-
公开(公告)号：US20090111778A1
公开(公告)日：2009-04-30
申请号：US12094139
申请日：2006-11-17
申请人： Richard Apodaca , J. Guy Breitenbucher , Matthew T. Epperson , Amy K. Fried , Daniel J. Pippel , Mark Seierstad
发明人： Richard Apodaca , J. Guy Breitenbucher , Matthew T. Epperson , Amy K. Fried , Daniel J. Pippel , Mark Seierstad
IPC分类号： A61K31/60 , A61K31/195 , A61K31/167 , A61K31/192 , A61K31/135 , C07D413/14 , A61K31/4545 , C07D413/06 , A61K31/454 , A61K31/498 , A61K31/5377 , A61P29/00 , A61P25/00 , A61P3/00 , A61P15/00 , A61P27/00 , A61P37/00 , A61P9/00
CPC分类号： C07D413/04 , C07D263/32 , C07D263/34 , C07D413/12 , C07D413/14
摘要： Certain 2-keto-oxazole compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译： 描述了某些2-酮 - 恶唑化合物，其可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。
-
2.发明授权Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase 有权芳基 - 羟乙基氨基 - 嘧啶和三嗪作为脂肪酸酰胺水解酶的调节剂公开(公告)号：US08598202B2
公开(公告)日：2013-12-03
申请号：US12378734
申请日：2009-02-18
申请人： Richard Apodaca , J. Guy Breitenbucher , Alison L. Chambers , Xiaohu Deng , Natalie A. Hawryluk , John M. Keith , Neelakandha S. Mani , Jeffrey E. Merit , Joan M. Pierce , Mark Seierstad , Wei Xiao
发明人： Richard Apodaca , J. Guy Breitenbucher , Alison L. Chambers , Xiaohu Deng , Natalie A. Hawryluk , John M. Keith , Neelakandha S. Mani , Jeffrey E. Merit , Joan M. Pierce , Mark Seierstad , Wei Xiao
IPC分类号： A01N43/54 , A61K31/505
CPC分类号： C07D239/42 , C07D239/47 , C07D239/48 , C07D251/22 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/12
摘要： Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.
摘要翻译： 描述了某些芳基 - 羟乙基氨基 - 嘧啶和三嗪化合物，其可用作FAAH抑制剂。 这些化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，能量代谢紊乱， 和运动障碍（例如多发性硬化）。 还公开了合成这些化合物的方法。
-
3.发明授权N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase 有权N-杂芳基哌嗪基脲作为脂肪酸酰胺水解酶的调节剂公开(公告)号：US07541359B2
公开(公告)日：2009-06-02
申请号：US11478128
申请日：2006-06-28
IPC分类号： A61K31/496 , A61K31/505 , A61K31/5377 , C07D285/135 , C07D417/04 , C07D417/12
CPC分类号： C07D285/08 , C07D417/04 , C07D417/12 , C07D417/14
摘要： Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译： 描述了如说明书中定义的某些式（I）的N-杂芳基哌嗪基脲化合物，其可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。
-
4.发明授权Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase 有权哌嗪基和哌啶基脲作为脂肪酸酰胺水解酶的调节剂公开(公告)号：US07598249B2
公开(公告)日：2009-10-06
申请号：US11321710
申请日：2005-12-29
IPC分类号： A61K31/497 , A61K31/445 , A01N43/40 , C07D241/04 , C07D211/00 , C07D295/00
CPC分类号： C07D295/195 , C07D207/335 , C07D209/08 , C07D209/14 , C07D209/82 , C07D211/16 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/18 , C07D239/42 , C07D241/42 , C07D295/20 , C07D295/215 , C07D307/79 , C07D307/81 , C07D317/46 , C07D317/58 , C07D319/16 , C07D319/18 , C07D333/58 , C07D333/60 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译： 某些哌嗪基和哌啶基脲化合物可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。
-
公开(公告)号：US08530476B2
公开(公告)日：2013-09-10
申请号：US12557650
申请日：2009-09-11
IPC分类号： A61K31/497 , C07D403/00 , C07D405/06 , C07D401/06
CPC分类号： C07D295/195 , C07D207/335 , C07D209/08 , C07D209/14 , C07D209/82 , C07D211/16 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/18 , C07D239/42 , C07D241/42 , C07D295/20 , C07D295/215 , C07D307/79 , C07D307/81 , C07D317/46 , C07D317/58 , C07D319/16 , C07D319/18 , C07D333/58 , C07D333/60 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
-
6.发明申请Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase 有权芳基 - 羟乙基氨基 - 嘧啶和三嗪作为脂肪酸酰胺水解酶的调节剂公开(公告)号：US20090264429A1
公开(公告)日：2009-10-22
申请号：US12378734
申请日：2009-02-18
申请人： Richard Apodaca , J. Guy Breitenbucher , Alison L. Chambers , Xiaohu Deng , Natalie A. Hawryluk , John M. Keith , Neelakandha S. Mani , Jeffrey E. Merit , Joan M. Pierce , Mark Seierstad , Wei Xiao
发明人： Richard Apodaca , J. Guy Breitenbucher , Alison L. Chambers , Xiaohu Deng , Natalie A. Hawryluk , John M. Keith , Neelakandha S. Mani , Jeffrey E. Merit , Joan M. Pierce , Mark Seierstad , Wei Xiao
IPC分类号： A61K31/5377 , A61K31/505 , C07D413/14 , C07D239/42
CPC分类号： C07D239/42 , C07D239/47 , C07D239/48 , C07D251/22 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/12
摘要： Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.
摘要翻译： 描述了某些芳基 - 羟乙基氨基 - 嘧啶和三嗪化合物，其可用作FAAH抑制剂。 这些化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，能量代谢紊乱， 和运动障碍（例如多发性硬化）。 还公开了合成这些化合物的方法。
-
公开(公告)号：US08906914B2
公开(公告)日：2014-12-09
申请号：US13390984
申请日：2010-08-17
申请人： Natalie A. Hawryluk , J. Guy Breitenbucher , William M. Jones , Alison L. Chambers , John M. Keith , Mark Seierstad
发明人： Natalie A. Hawryluk , J. Guy Breitenbucher , William M. Jones , Alison L. Chambers , John M. Keith , Mark Seierstad
IPC分类号： C07D239/42 , C07D403/12 , A61K31/506 , C07D417/12 , C07D413/04 , C07D409/12 , C07D409/04 , C07D401/04 , C07D413/12 , C07D405/12 , C07D405/04
CPC分类号： C07D239/42 , C07D401/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/12
摘要： Certain ethylene diamine compounds of Formula (I) are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.
摘要翻译： 描述了某些式（I）的乙二胺化合物，其可用作FAAH抑制剂。 这些化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，能量代谢紊乱， 和运动障碍（例如多发性硬化）。 还公开了合成这些化合物的方法。
-
8.发明申请PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE 有权作为脂肪酸酰胺水解酶的调节剂的哌嗪和哌啶酸公开(公告)号：US20100004261A1
公开(公告)日：2010-01-07
申请号：US12557650
申请日：2009-09-11
IPC分类号： A61K31/496 , C07D401/12 , C07D401/14 , C07D417/14 , A61P25/00 , A61P25/22 , A61P29/00 , A61P3/00 , A61P25/28 , A61P25/08 , A61P1/00 , A61P27/02 , A61P25/16 , A61P27/06 , A61P31/18 , A61P31/00 , A61P19/02 , A61P9/00 , A61P9/12 , A61P35/00 , A61P11/00 , A61P15/00 , A61P15/04 , A61P17/04
CPC分类号： C07D295/195 , C07D207/335 , C07D209/08 , C07D209/14 , C07D209/82 , C07D211/16 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/18 , C07D239/42 , C07D241/42 , C07D295/20 , C07D295/215 , C07D307/79 , C07D307/81 , C07D317/46 , C07D317/58 , C07D319/16 , C07D319/18 , C07D333/58 , C07D333/60 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译： 某些哌嗪基和哌啶基脲化合物可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。
-
公开(公告)号：US20090062294A1
公开(公告)日：2009-03-05
申请号：US12126389
申请日：2008-05-23
申请人： Richard Apodaca , J. Guy Breitenbucher , Natalie A. Hawryluk , William M. Jones , John M. Keith , Jeffrey E. Merit , Mark S. Tichenor , Amy K. Timmons
发明人： Richard Apodaca , J. Guy Breitenbucher , Natalie A. Hawryluk , William M. Jones , John M. Keith , Jeffrey E. Merit , Mark S. Tichenor , Amy K. Timmons
IPC分类号： A61K31/501 , C07D401/00 , C07D403/00 , C07D403/14 , A61P35/00 , A61P25/00 , A61P1/04 , A61P9/00 , A61P37/00 , A61P31/12 , A61P1/00 , A61K31/445 , A61K31/496
CPC分类号： C07D231/40 , C07D237/20 , C07D241/20 , C07D257/06 , C07D261/14 , C07D261/20 , C07D271/12 , C07D285/14 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要： Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
摘要翻译： 描述了某些杂芳基取代的哌啶基和哌嗪基脲化合物，其可用作FAAH抑制剂。 这些化合物可用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，胰岛素抵抗，糖尿病 ，骨质疏松症和运动障碍（例如，多发性硬化症）。
-
公开(公告)号：US07456208B2
公开(公告)日：2008-11-25
申请号：US11773049
申请日：2007-07-03
IPC分类号： A61K31/4172 , C07D233/64 , C07D233/54
CPC分类号： C07D401/04 , C07D233/26 , C07D405/04
摘要： Certain imidazole compounds are CCK1 modulators useful in the treatment of CCK1 mediated diseases.
摘要翻译： 某些咪唑化合物是可用于治疗CCK1介导的疾病的CCK1调节剂。
-
-
-
-
-
-
-
-
-
搜索结果
49 条记录 (耗时 0.047 秒)
